1. Scrip
  2. >>Archive

Video Interview: Rigontec CEO Details Immuno-Oncology Strategy

 
• By Mike Ward

Rigontec GmbH CEO Dr. Christian Schetter explains to Mike Ward, Informa Pharma Insights global director of content, how his company is developing a new class of RNA-based immunotherapeutics to treat cancers and viral diseases by targeting RIG-I, one of the essential pathways of the innate immune system. Rigontec's proprietary agonists are designed to activate RIG-I specifically, inducing both immediate and long-term anti-tumor immunity, and achieving substantial local and systemic tumor regression in several relevant in vivo models.

Rigontec GmbH CEO Dr. Christian Schetter explains to Mike Ward, Informa Pharma Insights global director of content, how his company is developing a new class of RNA-based immunotherapeutics to treat cancers and viral diseases by targeting RIG-I, one of the essential pathways of the innate immune system. Rigontec's proprietary agonists are designed to activate RIG-I specifically, inducing both immediate and long-term anti-tumor immunity, and achieving substantial local and systemic tumor regression in several relevant in vivo models.

With €14.25m from a series A round, Rigontec is looking to get its first RIG-I agonists into the clinic by the end of 1Q 2017 at the latest. It...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

Final Chance To Have Your Say: Take Scrip's Reader Survey This Week

 
• By Eleanor Malone

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 
• By Eleanor Malone

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access Scrip, or if you love it how it is, now is the time to have your voice heard.

Galapagos Expands Point-Of-Care CAR-T Study To The US

 
• By Andrew McConaghie

CEO Paul Stoffels said gaining US clearance for an IND for its novel CAR-T product was demanding, but now opens up a pathway towards a pivotal study starting in 2025.

Analysts Split On Eisai’s Chances Of Changing EU Regulator’s Mind On Leqembi

 
• By Andrew McConaghie

A final rejection of Leqembi could also spell the same fate for Lilly’s rival drug but public outcry and demand for Alzheimer’s therapies might force the regulator’s hand

More from Scrip

Merck & Co./Daiichi Pull Patritumab Deruxtecan BLA On Disappointing OS

 
• By Jessica Merrill

Patritumab deruxtecan is the lead antibody drug conjugate in a $22bn deal signed between the two partners, with the decision marking a disappointing setback

Executives On The Move: Innate Pharma And Alloy Therapeutics Get New CEOs

Pascal Soriot, CEO of AstraZeneca, joins Agilent Technologies' board, plus Zealand Pharma acquires chief development officer from UCB Biopharma.

Senti’s Computer-Logic Inspired Cell Therapy Shows Early Promise

 
• By Andrew McConaghie

The biotech believes its logic-gated cell therapies can get round the need for ‘clean targets’ which limit CAR-Ts and ADCs.